Clinical Data Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease PharmaTimesSubcutaneous delivery shows IVlevel efficacy in moderate to severe TEDClinical DataOphthalmologyRead full story pharminent April 7, 2026 (Last updated: April 7, 2026) PharmaTimes Subcutaneous delivery shows IVlevel efficacy in moderate to severe TED Clinical DataOphthalmologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing ChangesNext: Kennedy changes vaccine panel charter after legal setback Related Stories Clinical Data ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma pharminent June 2, 2026 Clinical Data ASCO26: In vivo oncology approaches continue to show promise pharminent June 2, 2026 Clinical Data ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come pharminent June 2, 2026
